Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Non-resectable Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Radiation: Proton radiotherapy Sponsors: Chang Gung Memorial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
Conditions: TNBC - Triple-Negative Breast Cancer Interventions: Drug: Utidelone; Drug: Tirelizumab; Drug: Bevacizumab Sponsors: Huihua Xiong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
BAT1308 Combined With Platinum-Based Chemotherapy ± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer
Conditions: Cervical Cancer Interventions: Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection; Drug: Cisplatin; Drug: Bevacizumab Injection; Drug: carboplatin; Drug: Paclitaxel for Injection Sponsors: Bio-Thera Solutions Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases
Conditions: Colorectal Cancer Interventions: Drug: Bevacizumab Combined With PD-1 Monoclonal Antibody Sponsors: The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
Conditions: Carcinoma, Ovarian Epithelial Interventions: Drug: Olaparib; Drug: Bevacizumab Sponsors: Mario Negri Institute for Pharmacological Research; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Drug: Durvalumab; Drug: Tremelimumab, Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma Interventions: Drug: Livmoniplimab; Drug: Budigalimab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Tremelimumab Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Conditions: Unresectable Metastatic Colorectal Cancer Interventions: Drug: ABBV-400; Drug: Bevacizumab; Drug: Folinic Acid; Drug: Fluorouracil; Drug: Irinotecan Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Conditions: Metastatic Colorectal Cancer; CRC; KRAS/NRAS Mutation Interventions: Drug: Onvansertib; Drug: FOLFIRI; Drug: Bevacizumab; Drug: FOLFOX Sponsors: Cardiff Oncology; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Conditions: Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab Sponsors: Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
Conditions: Thyroid Carcinoma; Surgery Interventions: Drug: Bevacizumab-IRDye800CW Sponsors: University Medical Center Groningen; Dutch Cancer Society Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
Conditions: Colorectal Cancer Interventions: Drug: Tas-102(Suyuan) combined with bevacizumab Sponsors: The Second Affiliated Hospital of Shandong First Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)
Conditions: Hepatocellular Carcinoma Interventions: Drug: Bevacizumab combined with Sintilimab; Procedure: Transcatheter arterial chemoembolization Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Conditions: Ovarian Cancer Interventions: Drug: Pembrolizumab; Drug: Bevacizumab; Drug: Cyclophosphamide Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Conditions: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; High Grade Endometrioid Ovarian Cancer; Primary Peritoneal Cancer; Fallopian-tube Cancer Interventions: Drug: Fluzoparib Capsules; Drug: Bevacizumab Sponsors: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
